Sensei Biotherapeutics, Inc. SNSE
Set alert
At close · Jun 15
After hours · Jun 15, 4:00 PM ET
- YTD
- +29.80%
- 1 year
- +85.16%
- Open
- 15.21
- Prev close
- 13.85
- Mkt cap
- 11.37M
- Vol
- 219.47K
- Avg vol
- 460.67K
- EPS
- -1.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.76
- High
- 16.52
- Forward P/E
- -0.40
- Beta
- 0.06
- Short ratio
- 0.29
- Inst. own
- 8.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 0.5072
- 200-d avg
- 0.747255
- 1y target
- 4.13
Key statistics
- Market cap
- 11.37M
- Enterprise value
- -35.62M
- Trailing P/E
- 0.00
- Forward P/E
- -0.40
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.17
- EPS (TTM)
- -1.19
- Beta
- 0.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -14.90M
- Total cash
- 52.29M
- Total debt
- 5.05M
- Return on equity
- -45.17%
- Shares outstanding
- 25.15M
- Short % of float
- 1.16%
- 50-day average
- 0.5072
- 200-day average
- 0.747255
Analyst view
Consensus: none
- Target (low)
- 3.50
- Target (mean)
- 4.13
- Target (high)
- 5.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.29984.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.31 | -0.29 | +0.02 | +6.45% |
| Aug 6, 2024 | Jun 1, 2024 | -0.25 | -0.28 | -0.03 | -12.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.25 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.29 | -0.32 | -0.03 | -10.34% |
| May 9, 2024 | Mar 1, 2024 | -0.29 | — | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -0.32 | -0.30 | +0.02 | +6.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 24, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| May 14, 2024 | Stephens & Co. | init | — | Overweight |
| Dec 4, 2023 | HC Wainwright & Co. | init | — | Buy |
| Dec 13, 2022 | Citigroup | init | — | Buy |
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- senseibio.com
News
- This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
- This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
- This Daktronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Nasdaq Surges Over 1%; US Durable Goods Orders Fall In December
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings
Your note
Sign in to keep a note on SNSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRODER SAMUEL | Director | Stock Award(Grant) | Jul 9, 2023 | 8,932 |
| CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 9, 2023 | 5,240,420 |
| CELEBI JOHN | Chief Executive Officer | Purchase | Sep 10, 2023 | 111,311 |
| ENGLISH JESSIE | Director | Stock Award(Grant) | Jul 9, 2023 | 8,932 |
| HOLMEN BOB | Director | Stock Award(Grant) | Jul 9, 2023 | 25,598 |
| HUMER KRISTIAN | Director | Stock Award(Grant) | Jul 9, 2023 | 8,932 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 2.58% | 650,000 | 293.80K | Sep 29, 2024 |
| Vanguard Group Inc | 2.46% | 618,757 | 279.68K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.86% | 215,572 | 97.44K | Sep 29, 2024 |
| Boothbay Fund Management, LLC | 0.69% | 172,835 | 78.12K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.65% | 163,139 | 73.74K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.36% | 90,428 | 40.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.93% | 485,960 | 219.65K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.40% | 99,616 | 45.03K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 90,441 | 40.88K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.19% | 47,900 | 21.65K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 28,330 | 12.80K | Oct 30, 2024 |
| Vanguard Balanced Index Fund | 0.07% | 18,109 | 8.19K | Sep 29, 2024 |